Top stories in endocrinology: FDA OKs first triple combination pill for diabetes, apps help people with diabetes lose weight

The FDA approved Trijardy XR, the first oral therapy to combine three type 2 diabetes medications into one pill. It was the week’s top story in endocrinology.

Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.

FDA approves first triple combination pill for type 2 diabetes

The FDA approved the first oral therapy to combine three type 2 diabetes medications into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release, according to a press release from Boehringer Ingelheim and Eli Lilly and Co. Read more.

Mobile apps may facilitate weight loss among adults with type 2 diabetes

Phone apps 
Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.
Source: Shutterstock

Adults with type 2 diabetes may lose weight more effectively by including a weight-loss mobile app as part of their strategy, according to findings from a meta-analysis published in Obesity. Read more.

New genetic discoveries help predict risk for type 1, type 2 diabetes

Researchers continue to discover more each year about the genetic risk factors for type 1 and type 2 diabetes and how those risk factors interact with the environment. Scientists have linked several genetic mutations to diabetes risk, though not everyone with a genetic mutation will go on to develop the disease. Read more.

Dual-hormone artificial pancreas ‘next logical treatment’ for type 1 diabetes

Adults with type 1 diabetes may be able to maintain their glucose levels in target range longer, particularly during the day, by using an artificial pancreas with rapid-acting insulin and pramlintide, according to findings published in Diabetes Care. Read more.

High childhood HbA1c increases premature death risk in type 1 diabetes

Young adults with type 1 diabetes were nearly three times more likely to die before age 30 years if they had poor metabolic control during childhood, according to findings from a Swedish registry-based study. Read more.

The FDA approved Trijardy XR, the first oral therapy to combine three type 2 diabetes medications into one pill. It was the week’s top story in endocrinology.

Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.

FDA approves first triple combination pill for type 2 diabetes

The FDA approved the first oral therapy to combine three type 2 diabetes medications into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release, according to a press release from Boehringer Ingelheim and Eli Lilly and Co. Read more.

Mobile apps may facilitate weight loss among adults with type 2 diabetes

Phone apps 
Another top story was about a study that found people with type 2 diabetes may lose weight more effectively if they used a weight-loss mobile app.
Source: Shutterstock

Adults with type 2 diabetes may lose weight more effectively by including a weight-loss mobile app as part of their strategy, according to findings from a meta-analysis published in Obesity. Read more.

New genetic discoveries help predict risk for type 1, type 2 diabetes

Researchers continue to discover more each year about the genetic risk factors for type 1 and type 2 diabetes and how those risk factors interact with the environment. Scientists have linked several genetic mutations to diabetes risk, though not everyone with a genetic mutation will go on to develop the disease. Read more.

Dual-hormone artificial pancreas ‘next logical treatment’ for type 1 diabetes

Adults with type 1 diabetes may be able to maintain their glucose levels in target range longer, particularly during the day, by using an artificial pancreas with rapid-acting insulin and pramlintide, according to findings published in Diabetes Care. Read more.

High childhood HbA1c increases premature death risk in type 1 diabetes

Young adults with type 1 diabetes were nearly three times more likely to die before age 30 years if they had poor metabolic control during childhood, according to findings from a Swedish registry-based study. Read more.